Since the company registration ninety-four events have happened. The last three records are Confirmation statement made on 23 November 2016 with updates; Full accounts made up to 31 December 2015; Appointment of Mr Brian Yoor as a director on 15 December 2015. The most likely internet sites of KNOLL UK INVESTMENTS UNLIMITED are www.knollukinvestments.co.uk, and www.knoll-uk-investments.co.uk. The predicted number of employees is 1 to 10. The company’s age is twenty years and eleven months. Knoll Uk Investments Unlimited is a Private Unlimited Company. The company registration number is 05294632. Knoll Uk Investments Unlimited has been working since 23 November 2004. The present status of the company is Active. The registered address of Knoll Uk Investments Unlimited is Abbott House Vanwall Business Park Vanwall Road Maidenhead Berkshire Sl6 4xe. . GOGAY, Kevan is a Secretary of the company. HALL, Gary James is a Director of the company. HUDSON, Susan Michelle is a Director of the company. YOOR, Brian is a Director of the company. Secretary BROWN, Stephen has been resigned. Secretary MARK, David has been resigned. Secretary POOTS, Kyle has been resigned. Nominee Secretary TRUSEC LIMITED has been resigned. Director BHIMJI, Nadia has been resigned. Director BROWN, Stephen has been resigned. Director COULTER, John has been resigned. Director FORREST, Andrew David Hall has been resigned. Director FREYMAN, Thomas Craig has been resigned. Director FUNCK, Robert Emmett has been resigned. Director HOLDEN, Elizabeth Jane Dilwihs has been resigned. Director HUDSON, Susan Michelle has been resigned. Director IGLESIAS FERNANDEZ, Luis has been resigned. Director MARK, David has been resigned. Director RANKIN, John Harry has been resigned. Director SMITH, Michael James has been resigned. Director SOENDERBY, Camilla Maria Kruchov has been resigned. Director STEWART, Jeffrey Ryan has been resigned. Director STOKER, Louise Jane has been resigned. Director ZUERCHER, Eleanor Jane has been resigned. The company operates in "Manufacture of basic pharmaceutical products".